Skip to main content

Table 2 Risk of graft loss at 24 months according to ΔeGFR and treatment

From: Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection

 

OR & (95% CI)

P value

Model

Change in ΔeGFR > 13 ml/min

5 (1.5 – 16.9)

0.006

Univariate

Treatment

1.2 (0.4 - 3.5)

0.736

Univariate

Change in ΔeGFR > 13 ml/min

5 (1.5 – 16.9)

0.006

Multivariate

Treatment

1.1 (0.3 - 3.4)

0.897

  1. ΔeGFR eGFR six months before diagnosis - eGFR at diagnosis of c-aABMR
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us